Loading...
Loading...
Oppenheimer says, “Our Generic Market Model includes news related to our Distribution/PBM and Labs coverage universe….We update our Generic Market Model to reflect July Rx data released by Wolters Kluwer.”
“Total generic Rx were up 8.3% y/y at 228.9M scripts. Rx growth in the broader prescription market was up 2.1% y/y. The month was driven by 2.0% y/y retail Rx growth and mail-order growth of 3.7% y/y. Retail numbers rebounded after a slow month in June and mail-order figures continue to be strong. While overall prescription volume is an important barometer, we would tend to focus more on generic volume growth, which remains fairly healthy,” the analysts add.
More Analyst Ratings here© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in